Correction to: A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial

Trials. 2020 Dec 14;21(1):1024. doi: 10.1186/s13063-020-04947-2.

¹ University Hospitals Leuven (UZ Leuven), Leuven, Belgium. timothy.devos@uzleuven.be.
² Catholic University of Leuven (KU Leuven), Leuven, Belgium. timothy.devos@uzleuven.be.
³ University Hospitals Leuven (UZ Leuven), Leuven, Belgium.
⁴ Catholic University of Leuven (KU Leuven), Leuven, Belgium.
⁵ Universitair Ziekenhuis Gent, Ghent, Belgium.
⁶ Instituut voor Tropische Geneeskunde, Antwerp, Belgium.
⁷ Sciensano, Elsene, Belgium.
⁸ Rode Kruis Vlaanderen, Mechelen, Belgium.
⁹ Universite Libre de Bruxelles Institut d 'Immunologie Medicale, Bruxelles, Belgium.
¹⁰ Universite de Liege, Liege, Belgium.
¹¹ Universite Libre de Bruxelles, Bruxelles, Belgium.
¹² Leuven Coordinating Centre, Leuven, Belgium.
¹³ Katholieke Universiteit Leuven Rega Institute for Medical Research, Leuven, Belgium.
¹⁴ Universitair Ziekenhuis Brussel, Bruxelles, Belgium.
¹⁵ Croix Rouge de Belgique, Bruxelles, Belgium.
¹⁶ Interuniversity Institute for Biostatistics and statistical Bioinformatics, Leuven, Belgium.
¹⁷ Universitair Ziekenhuis Antwerpen, Antwerpen, Belgium.
¹⁸ Cliniques Universitaires Saint-Luc, Sint-Lambrechts-Woluwe, Belgium.

No abstract available

Publication types